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Lipoic acid, also known as α-lipoic acid or
thioctic acid (LA, LA-(SS), 1,2-dithiolane-3-pen-
tanoic acid) and its reduced form dihydrolipoic acid
(DHLA, DHLA-(SH)2, 6,8-dimercaptooctanoic
acid) are present in all prokaryotic and eukaryotic
cells. The chemical structures of LA and DHLA are
shown in Figure 1. LA is synthesized in mammals in
the mitochondria of the liver and other tissues. It is
suggested that octanoic acid is the precursor of the
eight-carbon fatty acid chain of LA while cysteine is
the source of sulfur. Most of LA in the body is found
tightly bound to proteins by an amide linkage
(lipoamide, lipoyl group) to a lysine residue (lipolly-
sine). This lipoamide bond functions mainly as a
cofactor of multienzymatic mitochondrial complex-
es catalyzing oxidative decarboxylation of α-
ketoacids (1, 2). The lipoyl group can be oxidized
and reduced by lipoamide dehydrogenase.
Apart from endogenous synthesis, LA is also
absorbed from food. LA has been detected in the
form of lipollysine in various natural products. The
most important dietary sources of it include spinach,
broccoli and meat offal (3). Lipollysine absorbed
from the diet can be hydrolyzed in blood by lipoami-
dase. Moreover, LA has now become a common
ingredient of different formulas for athletes, anti-
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Abstract: Lipoic acid (LA-(SS), LA) and its reduced form - dihydrolipoic acid DHLA-(SH)2, DHLA) are syn-
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Figure 1. Chemical structures of lipoic acid (LA) and its reduced
form dihydrolipoic acid (DHLA)
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aging supplements and even pet food (4). In recent
years, pharmacological properties of exogenously
supplemented LA have attracted attention of many
researchers. It is suggested that therapeutic effects
of LA supplementation can be attributed to the
potent antioxidant properties of LA and DHLA.
The reductive potential of the LA/DHLA cou-
ple has been estimated at -320 mV (1) or -290 mV
(5). This means that DHLA is able to reduce not
only reactive oxygen and nitrogen species (ROS and
RNS, respectively) but also the oxidized forms of
other antioxidants, both hydrophilous, such as glu-
tathione disulfide (GSSG) and dehydroascorbic acid
(DHA), and hydrophobic, such as chromanoxyl rad-
ical of tocopherol (TOH) (6ñ10) (Table 1). For this
reason, DHLA is often called the antioxidant of
antioxidants or a universal antioxidant (11). The
oxidized form, i.e., LA has also been demonstrated
to express antioxidant properties (11, 12) (Table 2). 
Redox reactions are fundamental processes in
metabolism of all cells. A disruption of the pro- and
antioxidant balance can explain the mechanism of
etiopathogenesis and progression of many, appar-
ently distant pathological states. This is the reason
for an increasing significance of antioxidants in
medicine and more common use of the term ìoxida-
tive stressî in medical sciences. However, since the
activity of LA and DHLA as direct scavengers of
ROS/RNS was confirmed mostly by in vitro experi-
mental studies, some authors question the efficacy
Table 2. The scavenging capacity of LA and DHLA for the selected ROS and RNS. 
ROS/RNS LA DHLA Scavenging capacity  Reference 
O2
ï- no yes - (11)
no no - (12)
H2O2
yes yes LA < DHLA (11)
no yes  - (12)  
ïOH yes yes 
LA < DHLA (11)
LA = DHLA  (12)  
ONOO- yes yes LA < DHLA (11, 12)   
NOï yes yes LA < DHLA (11, 12) 
Table 1. The values of standard biological redox potentials (E0` ) of selected redox systems
System E0' (V) Reference
Acetic acid/acetaldehyde -0.60 (11)
Acetylo-CoA/acetaldehyde -0.41 (11)
NAD/NADH + H+ -0.32 (12, 14)
LA/DHLA -0.29 (5, 12, 13)
GSSG/GSH -0.24 (12)
Cystine/cysteine -0.22 (12, 15)
Acetaldehyde/ethanol -0.20 (11)
FAD/FADH2 -0.06 (11, 14)
Dehydroascorbic acid/ascorbic acid 0.08 (11, 12)






ïOH, H+/HïO 2.31 (15)
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of the supplemented nonprotein-bound LA as a
physiological antioxidant and underline the prob-
lem, overlooked until recently, related to the differ-
ential effects of LA in vitro and in vivo (13, 14). Our
research paper is a modest contribution to the ongo-
ing discussion on this issue. 
In the present study, we investigated in vitro
the inactivation of yeast aldehyde dehydrogenase
(ALDH) by nitroglycerin (glycerol trinitrate; GTN)
in the presence and absence of LA and DHLA.
Moreover, in vivo studies were performed to answer
the question whether LA administered jointly with
GTN will affect the ALDH activity in the rat liver. 
The genes encoding ALDHs were divided into
several families and subfamilies. It should be noted
that sequence comparison demonstrated that both
yeast and mammalian ALDH isozymes contained 
-SH groups that could form a wide variety of oxida-
tion products (15). 
EXPERIMENTAL
Reagents
In this study, the formulations Thiogamma and
Nitracor were used, which contain LA and GTN,
respectively, as pharmacologically active sub-
stances. Thiogamma was obtained from HexalÆ
AG, (Holzkirchen, Germany). Nitracor was pur-
chased from LEK S.A. and Pliva KrakÛw S.A.
(Poland). Purified yeast ALDH, as well as DHLA,
EDTA, Folin-Ciocalteau reagent, 4-methylpyrazole,
NAD, propionaldehyde and rotenone were provided
Scheme 1. Design of the experiment investigating yeast ALDH activity in vitro. Two series of enzyme mixtures were prepared. The final
concentration of ALDH was 0.3 mg/mL in all experiments. The concentration of thiols (LA and DHLA) in the enzyme mixtures was 1
mM
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by Sigma-Aldrich Chemical Company ((PoznaÒ,
Poland). All the other reagents were of analytical
grade and were obtained from Polish Chemical
Reagent Company (POCh, Gliwice, Poland). 
Animals
Animal experiments were conducted in accor-
dance with the guidelines for animal experiments of
Animal Research Committee and were approved by
the Jagiellonian University Ethic Committee. The
study was carried out on male Wistar rats using the
modified experimental design of Dudek et al. (16,
17). The animals were divided randomly into three
groups of 8 animals each. The first group was treat-
ed with 0.9% NaCl (0.6 mL, three times a day, s.c.)
for 8 days (control group). The second group was
treated with GTN (30 mg/kg b.w., s.c., divided into
three doses) for 8 days. The third group was treated
with GTN and LA jointly for 8 days (GTN 30 mg/kg
b.w., s.c., divided into three doses and LA 100
mg/kg b.w., i.p., divided into two doses, respective-
ly). 
Animals were sacrificed on the 9th day by cer-
vical dislocation and the livers were excised,
washed in 0.9% NaCl, placed in liquid nitrogen and
stored at -70OC until ALDH activity test was per-
formed.
Methods
Preparation of liver homogenates
The frozen livers were weighed and
homogenates were prepared by homogenization of 1
g of the tissue in 4 mL of 0.1 M phosphate buffer,
pH 7.4 using an IKA-ULTRA-TURRAX T8
homogenizer.
Determination of ALDH activity in the rat liver
homogenate
The assay mixture contained liver homogenate,
sodium phosphate buffer (pH 8.2), NAD, EDTA, 4-
methylpyrazole and rotenone. The reaction was initi-
ated by the addition of propionaldehyde as a sub-
strate. 4-Methylpyrazole was added to inhibit alcohol
dehydrogenase, and rotenone to inhibit mitochondri-
Table 3. The effect of GTN administered in combination with LA




Control group 45.28 ± 10.85  
GTN group 21.12***± 3.87  
GTN + LA group 26.25*** ± 5.38
***Differences significant at p < 0.001 in comparison to control
value. The activity of ALDH was calculated by using the molar
extinction coefficient of reduced NAD of 6.22 mM-1 cm-1 at 340
nm. Specific activity of the enzyme was expressed as nmol
NADH/min (U)/mg-protein.
Figure 2. The LA and DHLA-induced restoration of GTN-inhibited ALDH activity in vitro. The ALDH activity was assayed with propi-
onaldehyde (8 µM) as a substrate by measuring the reduction of NAD (1 mM) at 340 nm. Data are presented as a percentage relative to
the control (100%) (without GTN and thiols). Data are shown as the mean ± SD. Significant vs. control sample: ** p < 0.01; *** p < 0.001.
Significant vs. GTN sample: # p < 0.05, ### p < 0.001
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al NADH oxidase. The blank sample in which the
homogenate was omitted was run simultaneously.
The activity of ALDH was calculated using the
molar extinction coefficient of NADH of 6.22 
mM-1cm-1 at 340 nm with the use of a modified pro-
tocol published earlier (18, 19). Specific activity of the
enzyme was expressed as nmol of NADH produced
per 1 mg of protein per 1 min. The protein content was
measured using the method of Lowry et al. (20). 
Determination of yeast ALDH activity 
The final concentration of ALDH was 0.3
mg/mL in all experiments. The concentration of thi-
ols (LA and DHLA) in the enzyme mixtures was 1
mM. Two series of enzyme mixtures were prepared
(Scheme 1). All enzyme-containing mixtures were
incubated at a temperature of 25OC. 
Series I was prepared as follows:
Enzyme mixture 1. ALDH was preincubated
with 0.1 mM GTN in 50 mM sodium phosphate
buffer (pH 8) for 20 min. 
Enzyme mixture 2. ALDH was preincubated
with 0.1 mM GTN in 50 mM sodium phosphate
buffer (pH 8) for 5 min, then LA was added and the
mixture was incubated further for 15 min.
Enzyme mixture 3. ALDH was preincubated
with 0.1 mM GTN in 50 mM sodium phosphate
buffer (pH 8) for 5 min, then DHLA was added and
the mixture was incubated further for 15 min.
Series II was prepared as follows:
Enzyme mixture 1. ALDH was preincubated
with 0.1 mM of GTN in 50 mM sodium phosphate
buffer (pH 8) for 5 min.
Enzyme mixture 2. ALDH was preincubated
with LA in 50 mM sodium phosphate buffer (pH 8)
for 15 min, then 0.1 mM GTN was added and the
mixture was incubated further for 5 min.
Enzyme mixture 3. ALDH was preincubated
with DHLA in 50 mM sodium phosphate buffer (pH
8) for 15 min, then 0.1 mM GTN was added and the
mixture was incubated further for 5 min.
The assay mixture (1 mL) containing sodium
phosphate buffer (pH 8.2), propionaldehyde and NAD
was pipetted into a cuvette. The reaction was initiated
by the addition of the indicated enzyme mixture to the
cuvette and absorbance change at 340 nm was moni-
tored for 2 min at 25OC to calculate the rate of NADH
production and to compare it with the sample contain-
ing only ALDH without GTN (control sample). Data
are presented as a percentage relative to control (100%). 
Statistical analysis
All statistical calculations were carried out
with the STATISTICA 10.0 computer program
Figure 3. The LA and DHLA-induced prevention of ALDH inactivation by GTN in vitro. The ALDH activity was assayed with propi-
onaldehyde (8 µM) as a substrate by measuring the reduction of NAD (1 mM) at 340 nm. Data are presented as a percentage relative to
the control (100%) (without GTN and thiols). Data are shown as the mean ± SD. Significant vs. control sample: *** p < 0.001. Significant
vs. GTN sample: ## p < 0.01; ### p < 0.001.
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using a one-way ANOVA followed by the Tukey
post-hoc test. Data from in vitro studies are present-
ed as the mean ± SD of 3-4 independent experiments
in several repetitions. Data from in vivo experiments
are given as the mean ± SD for each group of ani-
mals. For all data, the values of p < 0.05 were con-
sidered to be statistically significant.
RESULTS 
Activity of ALDH in the rat liver homogenates
As shown in Table 3, the activity of ALDH in
the rat liver of the second group (GTN) and the third
group (GTN + LA) was statistically significantly
decreased vs. control group (first group). 
Activity of yeast-derived ALDH 
The results obtained in series I are presented in
Figure 2. The experiment indicated that 20-min
incubation with GTN induced a decrease in the
ALDH activity to 8.2% (mixture I) as compared to
the control (100%). A five-minute preincubation of
the enzyme with 0.1 mM GTN and then a 15-min
incubation with 1 mM thiols: LA or DHLA (mixture
2 and 3, respectively) caused a decrease in ALDH
activity to 31.6% and 71.9%, respectively, com-
pared to the control (100%). This indicates that both
1 mM thiols (LA and DHLA) were able to restore
ALDH activity inhibited by GTN, but DHLA was
more effective than LA.
The results obtained in series II are presented
in Figure 3. The experiment demonstrated that a 5-
min incubation with GTN lowered ALDH activity to
27% (mixture 1) compared to the control (100%).
When the samples of ALDH were preincubated with
1 mM LA or DHLA (mixture 2 and 3, respectively)
for 15 min and then with 0.1 mM GTN for 5 min, the
ALDH activity changed to 68.1% and 106.9%,
respectively, compared to the control (100%). 
This indicates that both 1 mM thiols (LA and
DHLA) were able to protect ALDH against the
inhibitory effect of GTN, but DHLA was more
effective than LA.
DISCUSSION AND CONCLUSIONS 
In line with literature data, the present studies
demonstrated that GTN inhibited ALDH activity
both in vivo and in vitro. Already in 1985, Towell et
al. (21) observed an 88% inhibition of erythrocytic
ALDH in GTN-treated patients. Wenzel et al. (22)
indicated that GTN was a potent inhibitor of both
purified yeast ALDH as well as ALDH in isolated
heart mitochondria from in vivo GTN-treated rats.
The next study of the same research group demon-
strated that GTN inhibited ALDH activity in circu-
lating white blood cells (WBCs) of healthy volun-
teers (23). The studies of Beretta et al. (24) showed
that GTN blocked ALDH activity in isolated rat
liver mitochondria, and also of recombinant human
ALDH. 
It is currently known that GTN is an inhibitor
of ALDH (i.e., causes the loss of dehydrogenase
activity) because it serves as a substrate for its
reductase activity. This means that ALDH catalyzes
the formation of glyceryl dinitrate (GDN) (1,2-
GDN/1,3-GDN ~ 8 : 1) and nitrite (NO2-) from
GTN. The electrons for this reduction are provided
by cysteine-thiols at the active site of ALDH that are
converted to an intramolecular disulfide bond,
which leads to a drop in the catalytic activity of the
enzyme (24ñ26). A simplified scheme of this
process can be expressed as:
GTN + ALDH-(SH)2 (active) → 1,2-GDN + NO2-
+ H+ + ALDH-(SS)(inactive)
The present results obtained in vitro support the
role of DHLA both in the restoration of ALDH
activity after inhibition by GTN and in the protec-
tion of the enzyme against the inhibitory effect of
GTN. ALDH activity was not inhibited by GTN if
DHLA was added prior to GTN. Also, DHLA large-
ly restored the inhibited ALDH activity if added
after GTN. It was confirmed by studies of other
authors. Namely, regeneration of the oxidized ñSH
groups of ALDH could be achieved via an exchange
with ñSH groups of DHLA (22, 24) what, in a sim-
plified way, can be expressed as:
ALDH-(SS)(inactive) + DHLA-(SH2) →
ALDH-(SH)2 (active) + LA-(SS)
Figure 4. Chemical structure of β-lipoic acid (β-LA). β-LA is a
biological oxidation product of LA, which was proven in in vitro,
but not in vivo studies (12, 27). 
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It is interesting and surprising that under in vitro
conditions also LA prevented inactivation of the
enzyme and had an impact on ALDH already inhibit-
ed by GTN. Since this is the first study examining the
effect of GTN on the ALDH activity in the presence
of the oxidized form of DHLA, i.e. LA, this result is
difficult to explain because of too few data. In vitro
studies revealed that LA was capable of scavenging
numerous ROS and RNS, which indicated that despite
being in its oxidized form LA behaved as a reducing
agent (antioxidant). β-Lipoic acid (β-LA) (Fig. 4) is a
biological oxidation product of LA, as demonstrated
only by in vitro studies (12, 27, 28). It means that
reduction process of the oxidized ñSH groups of
ALDH, in a simplified form, can be expressed as:
ALDH-(SS)(inactive) + LA-(SS) + H2O →
ALDH-(SH)2 (active) + β-LA
Is it possible? Further studies are necessary to
verify this undoubtedly intriguing hypothesis.
On the other hand, the in vivo experiments
indicated that treatment of rats with LA and GTN in
combination did not provide any protection against
GTN-induced ALDH inhibition. This is in contrast
with the results of Wenzel et al. (23), who reported
that administration of a single sublingual GTN dose
decreased ALDH activity in WBCs in healthy vol-
unteers and that these effects were prevented by oral
LA pretreatment 15 min before GTN. 
This difference could possibly be due to a
number of factors, including different experimental
conditions. In our opinion, the level of oxidative
stress is the core of the problem since oxidative
stress was undoubtedly much lower after GTN
administration at a single dose compared with
chronic GTN treatment (8 days). The sulfhydryl
groups of cysteine residues (Cys-SH) in proteins (P-
SH) can form a wide variety of oxidation products,
including reversible oxidation states of disulfide
bonds (P-SS) and sulfenic acid (P-SOH), and the
irreversible higher oxidation states of sulfinic acid
(P-SO2H) and sulfonic acid (P-SO3H) (15, 29).
Thus, the plausible proposal is that under our exper-
imental conditions in vivo the sulfhydryl groups of
cysteine residues at the active site of ALDH can be
irreversible oxidized to sulfinic acid (P-SO2H) and
sulfonic acid (P-SO3H) that cannot be reduced by
LA and DHLA, but in experimental conditions in
vivo described in the above-mentioned paper by
Wenzel et al. (23) the activity of the enzyme
decreased due to reversible oxidation of sulfhydryl
groups of cysteine residues in ALDH to disulfide
bonds that can be reduced by LA and DHLA. 
It should be mentioned that recent experi-
mental and clinical studies indicate a beneficial
effect of exogenous LA in many diseases accom-
panied by oxidative stress (30ñ36) and simultane-
ously, the ability of LA and DHLA to function as
physiological antioxidants is questioned (13, 14).
It means that the mechanism of pharmacological
actions of LA in vivo still remains undiscovered.
This issue definitely requires further studies the
more so that searching for the mechanisms of
pharmacological actions of LA is important from
the point of view of both basic research and its
practical applicability. 
In summary, the obtained results seem to con-
firm earlier reports indicating the differential effects
of LA in vitro and in vivo.
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